- Home
- IINN vs CANF Comparison
IINN vs CANF Comparison
Compare IINN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IINN
- CANF
- Stock Information
- Founded
- IINN 2018
- CANF 1994
- Country
- IINN Israel
- CANF Israel
- Employees
- IINN N/A
- CANF N/A
- Industry
- IINN Medical/Dental Instruments
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- IINN Health Care
- CANF Health Care
- Exchange
- IINN Nasdaq
- CANF Nasdaq
- Market Cap
- IINN 13.7M
- CANF 14.8M
- IPO Year
- IINN 2021
- CANF N/A
- Fundamental
- Price
- IINN $0.85
- CANF $1.03
- Analyst Decision
- IINN Strong Buy
- CANF Strong Buy
- Analyst Count
- IINN 1
- CANF 2
- Target Price
- IINN $2.00
- CANF $14.00
- AVG Volume (30 Days)
- IINN 422.8K
- CANF 129.3K
- Earning Date
- IINN 08-14-2025
- CANF 04-14-2025
- Dividend Yield
- IINN N/A
- CANF N/A
- EPS Growth
- IINN N/A
- CANF N/A
- EPS
- IINN N/A
- CANF N/A
- Revenue
- IINN N/A
- CANF $674,000.00
- Revenue This Year
- IINN N/A
- CANF $461.72
- Revenue Next Year
- IINN N/A
- CANF N/A
- P/E Ratio
- IINN N/A
- CANF N/A
- Revenue Growth
- IINN N/A
- CANF N/A
- 52 Week Low
- IINN $0.40
- CANF $0.98
- 52 Week High
- IINN $1.60
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- IINN 63.38
- CANF 39.89
- Support Level
- IINN $0.70
- CANF $1.02
- Resistance Level
- IINN $0.77
- CANF $1.09
- Average True Range (ATR)
- IINN 0.06
- CANF 0.04
- MACD
- IINN 0.01
- CANF -0.00
- Stochastic Oscillator
- IINN 75.80
- CANF 6.67
About IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).